share_log

Verve Therapeutics Slides As Insider Purchases Lose Another US$55k

Verve Therapeutics Slides As Insider Purchases Lose Another US$55k

由於內幕收購又損失了5.5萬美元,Verve Therapeutics下滑
Simply Wall St ·  05/22 11:41

The recent price decline of 11% in Verve Therapeutics, Inc.'s (NASDAQ:VERV) stock may have disappointed insiders who bought US$475.8k worth of shares at an average price of US$6.26 in the past 12 months. Insiders buy with the expectation to see their investments rise in value over a period of time. However, recent losses have rendered their above investment worth US$421.0k which is not ideal.

Verve Therapeutics, Inc.最近的價格下跌了11%。”s(納斯達克股票代碼:VERV)的股票可能會讓內部人士失望,他們在過去12個月中以6.26美元的平均價格購買了價值47.58萬美元的股票。內部人士買入時預計他們的投資價值將在一段時間內上漲。但是,最近的虧損使他們的上述投資價值爲421.0萬美元,這並不理想。

While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing.

儘管我們絕不會建議投資者僅根據公司董事的所作所爲做出決定,但我們確實認爲密切關注內部人士的所作所爲是完全合乎邏輯的。

The Last 12 Months Of Insider Transactions At Verve Therapeutics

Verve Therapeutics 過去 12 個月的內幕交易

In fact, the recent purchase by Andrew Ashe was the biggest purchase of Verve Therapeutics shares made by an insider individual in the last twelve months, according to our records. That means that an insider was happy to buy shares at above the current price of US$5.54. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. We always take careful note of the price insiders pay when purchasing shares. Generally speaking, it catches our eye when an insider has purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price. Andrew Ashe was the only individual insider to buy during the last year.

實際上,根據我們的記錄,安德魯·阿什最近的收購是內部人士在過去十二個月中對Verve Therapeutics股票的最大一筆收購。這意味着內部人士樂於以高於當前5.54美元的價格購買股票。儘管自收購以來,他們的看法可能發生了變化,但這至少表明他們對公司的未來充滿信心。我們始終仔細注意內部人士在購買股票時支付的價格。總的來說,當內部人士以高於當前的價格購買股票時,它會引起我們的注意,因爲這表明他們認爲即使價格更高,也值得買入。安德魯·阿什是去年唯一買入的內部人士。

The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

下圖顯示了去年的內幕交易(公司和個人)。如果你點擊圖表,你可以看到所有的個人交易,包括股價、個人和日期!

insider-trading-volume
NasdaqGS:VERV Insider Trading Volume May 22nd 2024
納斯達克股票代碼:VERV 內幕交易量 2024 年 5 月 22 日

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying.

還有許多其他公司有內部人士購買股票。你可能不想錯過這份內部人士正在收購的被低估的小盤股公司的免費清單。

Insider Ownership Of Verve Therapeutics

Verve Therapeutics的內部所有權

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. I reckon it's a good sign if insiders own a significant number of shares in the company. It appears that Verve Therapeutics insiders own 5.3% of the company, worth about US$25m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.

查看公司的內部持股總量可以幫助你了解他們是否與普通股股東保持一致。我認爲,如果內部人士擁有該公司的大量股份,這是一個好兆頭。看來Verve Therapeutics內部人士擁有該公司5.3%的股份,價值約2500萬美元。儘管這是一個強勁但並不突出的內部所有權水平,但這足以表明管理層與小型股東之間有一定的一致性。

What Might The Insider Transactions At Verve Therapeutics Tell Us?

Verve Therapeutics的內幕交易可能告訴我們什麼?

The recent insider purchase is heartening. And an analysis of the transactions over the last year also gives us confidence. But we don't feel the same about the fact the company is making losses. Insiders likely see value in Verve Therapeutics shares, given these transactions (along with notable insider ownership of the company). While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. Every company has risks, and we've spotted 4 warning signs for Verve Therapeutics (of which 1 is a bit concerning!) you should know about.

最近的內幕收購令人振奮。對去年交易的分析也使我們充滿信心。但是,我們對公司虧損的事實有不同的看法。鑑於這些交易(以及該公司顯著的內部所有權),內部人士可能會看到Verve Therapeutics股票的價值。雖然我們喜歡了解內部人士的所有權和交易情況,但在做出任何投資決策之前,我們一定要考慮股票面臨的風險。每家公司都有風險,我們已經發現了Verve Therapeutics的4個警告信號(其中一個有點令人擔憂!)你應該知道。

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

當然,通過尋找其他地方,你可能會找到一筆不錯的投資。因此,來看看這份有趣的公司的免費清單吧。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論